BiotechTube
Aquestive Therapeutics

Aquestive Therapeutics

AQSTApproved
Warren, United StatesFounded 2006aquestive.com

Aquestive Therapeutics is a publicly traded pharmaceutical company dedicated to advancing patient-centric medicines by simplifying complex drug delivery. With over 2 billion doses of its PharmFilm® products consumed globally and a robust intellectual property portfolio of 200+ patents, the company operates both a proprietary late-stage pipeline and a profitable contract development and manufacturing (CDMO) services business. Its strategic focus is on transmucosal delivery to overcome barriers in existing treatments for CNS disorders and severe allergic reactions, aiming to bring meaningful clinical improvements through its innovative oral film platform.

Market Cap
$479.6M
+22.0% period
Pipeline
10
1 in Phase 3
Patents
20
granted
Publications
5
indexed

AQST · Stock Price

USD 3.93+0.71 (+22.05%)

Historical price data

AI Company Overview

Aquestive Therapeutics is a publicly traded pharmaceutical company dedicated to advancing patient-centric medicines by simplifying complex drug delivery. With over 2 billion doses of its PharmFilm® products consumed globally and a robust intellectual property portfolio of 200+ patents, the company operates both a proprietary late-stage pipeline and a profitable contract development and manufacturing (CDMO) services business. Its strategic focus is on transmucosal delivery to overcome barriers in existing treatments for CNS disorders and severe allergic reactions, aiming to bring meaningful clinical improvements through its innovative oral film platform.

Allergy & ImmunologyCentral Nervous System (CNS)Dermatology

Technology Platform

Proprietary PharmFilm® oral film technology for transmucosal (buccal/sublingual) drug delivery, enabling rapid onset, improved bioavailability, and patient-friendly administration of complex molecules.

Pipeline

10
10 drugs in pipeline1 in Phase 3
DrugIndicationStageWatch
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg w...EpilepsyPhase 3
Riluzole Oral Soluble film (ROSF) 50 mgAmyotrophic Lateral SclerosisPhase 2
Diazepam Buccal FilmEpilepsyPhase 2
Diazepam Buccal Film 12.5 mgEpilepsyPhase 2
Riluzole Oral Soluble FilmALSPhase 2

FDA Approved Drugs

1
SYMPAZANNDANov 1, 2018

Opportunities

Major near-term opportunity lies in the successful approval and commercialization of AQST-109, which could capture significant share in the multi-billion dollar epinephrine market.
The growing demand for patient-friendly, non-invasive drug delivery across therapeutic areas presents a sustained opportunity for the PharmFilm® CDMO and licensing platform to expand its partner base and product portfolio.

Risk Factors

Key risks include clinical/regulatory failure or delay of AQST-109, challenges in commercializing a novel anaphylaxis treatment against entrenched auto-injectors, dependence on partners for a portion of revenue, and the capital-intensive nature of late-stage development and launch preparations.

Competitive Landscape

Competes against established epinephrine auto-injectors (EpiPen, Auvi-Q) and other rescue therapies in CNS. Differentiation is driven by Aquestive's proven PharmFilm® platform, extensive IP, and integrated development-to-manufacturing capabilities for creating convenient, needle-free alternatives.